Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-associated mortality worldwide. No effective treatment has been established for unresectable advanced HCC, and the prognosis is poor. Sorafenib is an oral multi-targeted tyrosine kinase inhibitor for unresectable advanced HCC th...

Descripción completa

Detalles Bibliográficos
Autores principales: SHIOZAWA, KAZUE, WATANABE, MANABU, IKEHARA, TAKASHI, MATSUKIYO, YASUSHI, KOGAME, MICHIO, KANAYAMA, MASAHIRO, MATSUI, TEPPEI, KIKUCHI, YOSHINORI, ISHII, KOJI, IGARASHI, YOSHINORI, SUMINO, YASUKIYO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861562/
https://www.ncbi.nlm.nih.gov/pubmed/24348819
http://dx.doi.org/10.3892/ol.2013.1664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861562/
https://www.ncbi.nlm.nih.gov/pubmed/24348819
http://dx.doi.org/10.3892/ol.2013.1664

Ejemplares similares